RNAC: Bullish Engulfing detected on 10 Mar 2026

A bullish engulfing pattern is forming in RNAC at $9.02, positioned within 82 days of a post-collapse recovery structure with a quality score of 31.0. The pattern demonstrates exceptional technical merit: structure scores 15.0/15, volume 12.0/12, and breakout 10.4/13, yielding an overall score of 87.4/98 and 78.06% win probability. Price sits 50.84% above the 52-week low and 52.02% below the 52-week high. Key support anchors at $6.08 with resistance at $9.16, creating a tight consolidation zone critical for breakout validation.

Cartesian Therapeutics reported full-year 2025 financial results on March 09, 2026, the day of pattern detection. Net loss widened to $130.3M as Cartesian ramps Phase 3 AURORA and prepares 2026 TRITON myositis trial, with $126.9M cash expected to last into mid‑2027. Enrollment is on track in the randomized, double-blind Phase 3 AURORA trial (~100 AChR Ab+ MG participants), and the FDA accepted an IND for a seamless adaptive Phase 2 myositis trial (TRITON) up to 50 participants with an interim analysis after 10 participants to inform a potential single pivotal trial in 1H26. Peer-reviewed Nature Medicine publications describe mechanism of action and 12-month durable responses; a biologic-naive subgroup (n=7) showed 57% minimal symptom expression at Month 6 sustained to Month 12. Needham maintained a 'Buy' rating and raised the price target from USD 40.00 to USD 42.00 on January 09, 2026, validating clinical momentum heading into earnings.

The bullish engulfing setup targets a measured move to $9.63 (conservative target), requiring volume confirmation above current 10.68x relative volume ratio. The pattern succeeds if price closes decisively above $9.16 resistance with sustained institutional buying flow—a 78% probability suggests strong structural support. Invalidation triggers at $6.08 support breach, which would represent a technical break of the post-collapse recovery structure and signal mean reversion risk to lower consolidation zones.

Critical headwind: healthcare sector regime is bearish (-0.23 regime score), contrasting the stock's recent 43.63% one-month gain. Recent earnings updates often paired positive cash runway and pipeline news with modestly negative next-day moves, suggesting a tendency for cautious reactions even to constructive updates. RSI at 65.8 approaches overbought thresholds, and beta of 1.54 means 54% higher volatility than broad market. ATR at 9.53% signals elevated daily swings. Phase 3 AURORA trial outcomes remain binary catalysts—enrollment on track, but clinical data won't arrive until later 2026 or 2027. Sector headwinds could pressure valuations despite fundamental progress.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.